What is Kernicterus Jaundice (Severe Neonatal Jaundice)?
Kernicterus, also called **severe neonatal jaundice**, is a rare but serious complication of newborn hyperbilirubinemia. It occurs when high levels of unconjugated bilirubin cross the immature blood‑brain barrier and deposit in the basal ganglia and brainstem. The resulting neuronal damage can cause permanent neurologic deficits, including hearing loss, movement disorders, and developmental delays. While most newborns develop some degree of jaundice in the first week of life, only a small fraction progress to the bilirubin concentrations that put the brain at risk.
Early recognition and prompt treatment are essential because the neurologic injury from kernicterus is often irreversible. The condition is most commonly seen in pre‑term infants, infants with hemolytic disease, or newborns with inadequate feeding that leads to excessive bilirubin production.
Key points
- Kernicterus is caused by toxic levels of unconjugated bilirubin (typically >20 mg/dL in term infants, lower in pre‑term).
- It is a medical emergency; early phototherapy or exchange transfusion can prevent brain injury.
- Long‑term outcomes depend on how quickly bilirubin is lowered and the extent of neural exposure.
Common Causes
Several conditions increase bilirubin production, impair bilirubin conjugation, or reduce bilirubin excretion, thereby predisposing a newborn to severe jaundice and kernicterus.
- Hemolytic disease of the newborn (HDN) – maternal‑fetal blood group incompatibility (e.g., ABO or Rh incompatibility).
- Genetic enzyme deficiencies – such as glucose‑6‑phosphate dehydrogenase (G6PD) deficiency, hereditary spherocytosis, or Gilbert’s syndrome.
- Breast‑feeding jaundice – inadequate milk intake in the first 48–72 hours leading to dehydration and reduced bilirubin clearance.
- Breast‑milk jaundice – substances in breast milk that inhibit bilirubin conjugation (usually peaks at 2–3 weeks).
- Prematurity – immature liver enzymes and a higher red‑cell turnover.
- Sepsis or other serious infections – increase hemolysis and impair hepatic function.
- Cephalohematoma or large bruises – massive breakdown of red blood cells beneath the skin.
- Crigler‑Najjar syndrome type I – rare autosomal‑recessive disorder with absent bilirubin‑UGT1A1 activity.
- Medications or toxins – certain antibiotics (e.g., sulfonamides), chloramphenicol, or excessive use of phenobarbital.
- Delayed meconium passage – leads to enterohepatic circulation of bilirubin.
Associated Symptoms
While jaundice itself is visible as yellowing of the skin and sclera, kernicterus may present with additional neurologic and systemic signs.
- Yellow discoloration of the skin beginning at the head and spreading downward.
- Yellowing of the eyes (scleral icterus) that does not fade with blanching.
- Lethargy or excessive sleepiness.
- Poor feeding or difficulty latching.
- High‑pitched cry or “high‑frequency” squeal.
- Hypotonia (floppiness) or, conversely, hypertonia (stiffness) of limbs.
- Seizure activity – focal or generalized.
- Abnormal eye movements (nystagmus) or ophthalmologic signs.
- Hearing impairment (later in life) due to auditory nerve involvement.
- Ataxia, dystonia, or other movement disorders that may emerge months after the acute episode.
When to See a Doctor
Newborns should be evaluated for jaundice within the first 24 hours if they have risk factors (e.g., prematurity, HDN). Parents should contact a pediatrician or go to an urgent care center promptly if they notice any of the following:
- Yellowing of the skin or eyes that spreads or deepens after the first 24 hours.
- Baby is sleeping more than usual, difficult to arouse, or unusually limp.
- Feeding problems: poor latch, reduced intake, or vomiting.
- High‑pitched crying, sudden changes in tone, or jerky movements.
- Any seizure‑like activity (stiffening, rhythmic jerking, eye deviation).
- Fever >38 °C (100.4 °F) or signs of infection (poor skin perfusion, mottling).
Early evaluation can prevent progression to kernicterus. If a baby is younger than 72 hours and has visible jaundice, it is considered an urgent assessment.
Diagnosis
Physicians use a combination of visual assessment, quantitative testing, and imaging to determine the severity of hyperbilirubinemia and whether kernicterus is developing.
1. Clinical Examination
- Transcutaneous bilirubinometer (TcB) – non‑invasive skin measurement.
- Physical exam for distribution of jaundice, tone, reflexes, and feeding behavior.
2. Laboratory Tests
- Serum total bilirubin (TB) and direct bilirubin – the core value; >20 mg/dL in term infants is a red flag.
- Complete blood count (CBC) – to assess hemolysis (elevated reticulocyte count, low hemoglobin).
- Blood type and Coombs test – to detect ABO/Rh incompatibility.
- G6PD level (if indicated), liver function tests, and viral cultures (e.g., TORCH).
- Blood glucose and electrolytes if the infant is unstable.
3. Imaging & Neuro‑assessment
- Transcranial ultrasound – may show basal ganglia echogenicity in severe cases.
- MRI – definitive for detecting bilirubin‑related injury (hyperintensity in globus pallidus).
- Auditory brain‑stem response (ABR) testing for hearing loss, especially after a kernicterus episode.
4. Risk‑Stratification Tools
Clinicians often reference the American Academy of Pediatrics (AAP) bilirubin nomogram and the NHBPEP guidelines to decide on phototherapy or exchange transfusion thresholds.
Treatment Options
Therapeutic goals are to rapidly lower serum unconjugated bilirubin and to support the infant’s hydration and nutrition.
1. Phototherapy
- First‑line therapy for most cases of severe jaundice.
- Uses blue‑green light (≈460 nm) to convert bilirubin into water‑soluble isomers that can be excreted without conjugation.
- Types: conventional overhead lights, fiber‑optic blankets, or LED phototherapy pads.
- Typically continued until bilirubin falls below the treatment threshold (often 12–16 mg/dL in term infants).
2. Exchange Transfusion
- Indicated when bilirubin is critically high (>20–25 mg/dL in term infants) or if phototherapy fails.
- Procedure replaces the infant’s blood with donor blood, rapidly removing bilirubin‑laden erythrocytes.
- Requires central venous or arterial access and close monitoring for complications (electrolyte imbalance, infection, thrombosis).
3. Intravenous Immunoglobulin (IVIG)
- Useful in hemolytic disease due to maternal antibodies (Rh/ABO incompatibility).
- IVIG blocks Fc receptors, decreasing hemolysis and bilirubin production.
4. Supportive Care
- Fluids – maintain adequate hydration; consider IV glucose if oral feeds are insufficient.
- Feeding – encourage frequent breastfeeding or formula supplementation to increase stool frequency and bilirubin elimination.
- Monitoring – serial bilirubin measurements every 4–6 hours during intensive treatment.
5. Long‑Term Management
- Hearing evaluation (ABR) at 3, 6, and 12 months.
- Developmental follow‑up with neurology or developmental pediatrics.
- Physical therapy for motor deficits if present.
Prevention Tips
Most cases of severe neonatal jaundice can be avoided with vigilant prenatal care, early newborn assessment, and proper feeding practices.
- Prenatal screening: Identify maternal blood type, antibody screen, and G6PD status when indicated.
- Early newborn assessment: Perform bilirubin measurement before discharge (typically at 24 hours for term infants, earlier for high‑risk newborns).
- Encourage effective feeding: Initiate breastfeeding within the first hour of life and ensure at least 8–12 wet diapers per day.
- Watch for risk factors: Prematurity, bruising, cephalohematoma, or family history of hemolytic disease merit closer bilirubin monitoring.
- Avoid excessive sun exposure: While sunlight can lower bilirubin, it is unreliable and may increase the risk of skin damage.
- Educate parents: Provide written instructions on what jaundice looks like and when to seek care.
- Consider prophylactic phototherapy: In extremely high‑risk infants (e.g., <35 weeks gestation), early prophylactic phototherapy can prevent dangerous rises.
Emergency Warning Signs
These findings require immediate medical attention—call emergency services (911) or go to the nearest emergency department.
- Sudden increase in yellowing, especially if it spreads rapidly.
- Severe lethargy or inability to awaken for feeding.
- High‑pitched cry, choking, or sudden changes in tone (rigidity or floppiness).
- Seizure activity (staring, rhythmic jerking, eye deviation).
- Temperature < 35 °C (95 °F) or >38.5 °C (101.3 °F) with jaundice.
- Rapid breathing, grunting, or cyanosis (bluish lips/face).
- Persistent vomiting or refusal to feed for >4 hours.
**References**
- American Academy of Pediatrics. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022.
- Mayo Clinic. Kernicterus. https://www.mayoclinic.org
- World Health Organization. Guidelines on the management of neonatal jaundice. 2021.
- National Institutes of Health, National Institute of Child Health & Human Development. Neonatal Jaundice. 2023.
- Cleveland Clinic. Phototherapy for newborn jaundice. 2022.